AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs), in a transaction valued at approximately $2.4 billion. The acquisition is part of AstraZeneca’s goal to deliver cancer treatments that replace traditional regimens like chemotherapy and radiotherapy with more targeted treatments. RCs have emerged as a promising modality in cancer treatment. These medicines del...